Plöckinger, Ursula : Akromegalie: Eine Analyse der therapeutischen Optionen und Erfolge


1. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. "Epidemiology of acromegaly in the Newcastle region." Clin Endocrinol. 1980 ; 12: 71-79.

2. Nabarro JDN. "Acromegaly." Clin Endocrinol. 1987 ; 26: 481-512.

3. Bengtsson B-Å, Edén S, Ernest I, Odén A, Sjögren B. "Epidemiology and long-term survival in acromegaly." Acta Med Scand. 1988 ; 223: 327-335.

4. Ritchie CM, Atkinson AB, Kennedy AL, Lyons AR, Gordon DS, Fannin T, Hadden DR . "Ascertainment and natural history of treated acromegaly in Northern Ireland." Ulster Med J. 1990 ; 59: 55-62.

5. Etxabe J, Gaztambide S, Latorre P, Vazquez JA. "Acromegaly: An epidemiological study." J Endocrinol Invest. 1993 ; 16: 181-187.

6. Bates AS, Van't Hoff W, Jones JM, Clayton RN. "An audit of outcome of treatment in acromegaly." Q J Med. 1993 ; 86: 293-299.

7. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. "Determinants of clinical outcome and survival in acromegaly." Clin Endocrinol. 1994 ; 41: 95-102.

8. Bates AS, Van't Hoff W, Jones JM, Clayton RN. "Does treatment of acromegaly affect life expectancy." Metabolism. 1995 ; 44(Suppl1): 1-5.

9. Quabbe H-J, Plöckinger U. "Acromegaly: Clinical findings and endocrinology. " In: Landolt AM, Vance ML, Reilly PL (eds.). Pituitary Adenomas: Biology, Diagnosis and Treatment. Churchill Livingstone, New York 1996 ; 85-100

10. Thorner MO, Frohman LA, Leong DA, Thominet J, Downs T, Hellmann P, Chitwood J, Vaughan JM, Vale W, Besser M, Lytras N, Edwards CRW, Schaaf M, Gelato M, Krieger DT, Marcovitz S, Ituarte E, Boyd AE, Malarkey WB, Blackard WG, Prioleau G, Melmed S, Charest NJ. "Extrahypothalamic growth-hormone-releasing factor (GRF) secretion is a rare cause of acromegaly: Plasma GRH levels in 177 acromegalic patients." J Clin Endocrinol Metab. 1984 ; 59: 846-849.

11. Werder K von, Losa M, Müller OA, Schweiberer L, Fahlbusch R, Pozo E del. "Treatment of metastasising GRF-producing tumour with a long-acting somatostatin analogue." Lancet. 1984 ; II: 282-283.

12. Barkan AL, Shenker Y, Grekin RJ, Vale WW, LLoyd RV, Beals TF. "Acromegaly due to ectopic growth hormone (GH)-releasing hormone (GHRH) production: Dynamic studies of GH and ectopic GHRH secretion." J Clin Endocrinol Metab. 1986 ; 63: 1057-1064.

13. Losa M, Wolfram G, Mojto J, Schopohl J, Spiess Y, Huber R, Müller OA, Werder K von. "Presence of growth hormone-releasing hormone-like immunoreactivity in human tumors: Characterization of immunological and biological properties. " J Clin Endocrinol Metab. 1990 ; 70: 62-68.

14. Asa SL, Kovacs K . "Pituitary pathology in acromegaly." In: Melmed S (ed.). Acromegaly. Endocrinology and Metabolism Clinics of North America. WB Saunders, Philadelphia 1992 ; 21: 553-574.

15. Saeger W, Puchner MJA, Lüdecke DK. "Combined sellar gangliocytoma and pituitary adenoma in acromegaly or Cushing´s disease." Virchows Arch. 1994 ; 425: 93-99.

16. Horvath E, Kovacs K, Scheithauer BW, Lloyd RV, Smyth HS. "Pituitary adenoma with neuronal choristoma (PANCH): composite lesion or lineage infidelity." Ultrastructural Pathology. 1994 ; 18: 565-574.

17. Puchner MJA, Lüdecke DK, Saeger W, Riedel M, Asa SL. "Gangliocytomas of the sellar region - a review." Exp Clin Endocrinol. 1995 ; 103: 129-149.

18. Losa M, Werder K von. "Pathophysiology and clinical aspects of the ectopic GH-releasing hormone syndrome." Clin Endocrinol. 1997 ; 47: 123-135.

19. Brandi ML, Marx SJ, Aurbach GD, Fitzpatrick LA. "Familial multiple endocrine neoplasia type I: A new look at pathophysiology." Endocrine Rev. 1987 ; 8: 391-405.

20. Pun KK, Chan G, Kung A, Lam K, Chan FL, Wang C. "McCune-Albright syndrome with acromegaly." Horm Metabol Res. 1989 ; 21: 527-528.

21. Chanson P, Dib A, Visot A, Derome PJ. McCune-Albright syndrome and acromegaly: Clinical studies and responses to treatment in five cases. Eur J Endocrinol. 1994 ; 131: 229-234.

22. Klein I. "Acromegaly and cancer. " Ann Intern Med. 1984 ; 101: 706-707.

23. Ituarte EA, Petrini J, Hershman JM. "Acromegaly and colon cancer." Ann Intern Med. 1984 ; 101: 627-628.

24. Ezzat S, Melmed S ". Are patients with acromegaly at increased risk for neoplasia." J Clin Endocrinol Metab. 1991 ; 72: 245-249.

25. Ladas SD, Thalassinos NC, Ioannides G, Raptis SA. "Does acromegaly really predispose to an increased prevalence of gastrointestinal tumours." Clin Endocrinol. 1994 ; 41: 597-601.

26. Delhougne B, Deneux C, Abs R, Chanson P, Fierens H, Laurent-Puig P, Duysburgh I, Stevenaert A, Tabarin A, Delwaide J, Schaison G, Belaiche J, Beckers A. "The prevalence of colonic polyps in acromegaly: A colonoscopic and pathological study in 103 patients." J Clin Endocrinol Metab. 1995 ; 80: 3223-3226.

27. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Gligorovic M, Penezic Z, Vuljovic S, marinkovic J and Pituitary Study Group. "Benign and malignant tumors in patients with acromegaly." In: Werder K von, Fahlbusch R. (eds.). Pituitary adenomas: From basic research to diagnosis and therapy. Elsevier, Amsterdam 1996 ; 61-67.

28. Molitch ME. "Clinical manifestations of acromegaly." In: Melmed S (ed.). Acromegaly. Endocrinology and Metabolism Clinics of North America. WB Saunders, Philadelphia 1992 ; 21:

29. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. "Acromegaly: Clinical and biochemical features in 500 patients." Medicine. 1994 ; 73: 233-240.

30. Nyquist P, Laws ER Jr, Elliott E. "Novel features of tumors that secrete both growth hormone and prolactin in acromegaly." Neurosurgery. 1994 ; 35: 179-182.

31. Asa LA. "The pathology of pituitary tumors." In: Molitch EM (ed.). Advances in pituitary tumor therapy. Endocrinology and Metabolism Clinics of North America. WB Saunders, Philadelphia 1999 ; 28: 13-44.

32. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Werder K von, Melmed S. "Criteria for cure of acromegaly: A consensus statement." J Clin Endocrinol Metab . 2000 ; 85: 526-529.

33. Levitt NS, Ratanjee BD, Abrahamson MJ. "Do „so-called“ normal growth hormone concentrations (2-5 µg/l) indicate cure in acromegaly." Horm Metab Res. 1995 ; 27: 185-188.

34. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. "Recent advances in pathogenesis, diagnosis, and management of acromegaly." J Clin Endocrinol Metab. 1995 ; 80: 3395-402.

35. Fahlbusch R, Honegger J, Buchfelder M. "Surgical management of acromegaly." In: Melmed S (ed.). Acromegaly. Endocrinology and Metabolism Clinics of North America. WB Saunders, Philadelphia 1992 ; 21: 669-692.

36. Eastman RC, Gorden P, Glatstein E, Roth J. "Radiation therapy of acromegaly." In: Melmed S (ed.). Acromegaly. Endocrinology and Metabolism Clinics of North America. WB Saunders, Philadelphia 1992 ; 21: 693-712

37. Engenhart-Cabillic R, Kocher M, Müller R-P, Voges J, Sturm V, Jockenhövel F, Fahlbusch R, Mokry M, Quabbe H-J. "Leitlinien zur Strahlentherapie von Hypophysenadenomen." Dtsch med Wschr. 1999 ; 124: 1148-1152

38. Thorén M, Rähn T, Guo WY, Werner S. "Stereotactic radiosurgery with the Cobalt-60 gamma unit in the treatment of growth hormone-producing pituitary tumors." Neurosurgery. 1991 ; 29: 663-668.

36. Ganz JC, Backlund EO, Thorsen FA. "The effects of gamma knife surgery of pituitary adenomas on tumor growth and endocrinopathies." Stereotact Funct Neurosurg. 1993 ; 61(Suppl1): 30-37.

40. Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Silvestrini F ". Inhibitory effect of L-Dopa on GH release in acromegalic patients." J Clin Endocrinol Metab. 1972 ; 35: 941-943.

41. Chiodini PG, Liuzzi A, Botalla L, Cremascoli G, Silvestrini F. "Inhibitory effect of dopaminergic stimulation on GH release in acromegaly." J Clin Endocrinol Metab. 1974 ; 38: 200-206.

42. Jaffe CA, Barkan AL. "Treatment of acromegaly with dopamine agonists." In: Melmed S (ed .). Acromegaly. Endocrinology and Metabolism Clinics of North America. WB Saunders, Philadelphia 1992 ; 21: 713-735.

43. Chiodini PG, Attanasio R, Cozzi R, Dallabonzana D, Oppizzi G, Orlandi P, Strada S, Liuzzi A. "CV 205-502 in acromegaly." Acta Endocrinol. 1993 ; 128: 389-393.

44. Lombardi G, Colao A, Ferone D, Sarnacchiaro F, Marzullo P, Sarno AD, Rossi E, Merola B. "CV 205-502 treatment in therapy-resistant acromegalic patients." Eur J Endocrinol. 1995 ; 132: 559-564.

45. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J. SMS 201-995: "A very potent and selective octapeptide analogue of somatostatin with prolonged action." Life Sci. 1982 ; 31: 1133-1140.

46. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA, Melmed S. "Octreotide treatment of acromegaly. A randomized, multicenter study." Ann Intern Med. 1992 ; 117: 711-718.

47. Lamberts SWJ, Reubi JC, Krenning EP. "Somatostatin analogs in the treatment of acromegaly." In: Melmed S (ed) . Acromegaly. Endocrinology and Metabolism Clinics of North America. WB Saunders, Philadelphia 1992 ; 21: 737-752.

48. Fløgstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns Ch, Jervell J. "Sandostatin LAR in acromegalic patients: A dose-range study." J Clin Endocrinol Metab. 1995 ; 80: 3601-3607.

49. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ. "Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate." J Clin Endocrinol Metab. 1988 ; 67: 1040-1048.

50. Stevenaert A, Harris AG, Kovacs K, Beckers A. "Presurgical octreotide treatment in acromegaly." Metabolism. 1992 ; 41(Suppl2): 51-58.

51. Lucas-Morante T, García-Uría J, Estrada J, Saucedo G, Cabello A, Alcañiz J, Barceló B. "Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery." J Neurosurg. 1994 ; 81: 10-14.

52. Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe H-J. "Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. " J Clin Endocrinol Metab. 1994 ; 79: 1416-1423.

53. Cunningham BC, Ultsch M, de Vos AM, Mulkerrin MG, Clauser KR, Wells JA. "Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule ." Science. 1991 ; 254: 821-825.

54. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, Lely AJ van der, Dimaraki EV, Stewart PM, Friend K, Vance ML, Besser GM, Scarlett JA. "Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant." New Engl J Med . 2000 ; 342: 1171-1177.

55. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC, Bennet WF. "Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. " J Clin Endocrinol Metab. 1999 ; 84: 2098-2103.

56. Hattori N, Shimatsu A, Kato Y, Koshiyama H, Ishikawa Y, Assadian H, et al. "Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly." J Clin Endocrinol Metab. 1990 ; 70: 771-776.

57. Wilson CB. A decade of pituitary microsurgery. J Neurosurg. 1984 ; 61: 814-833.

58. Lundin P, Pedersen F. "Volume of pituitary macroadenomas: Assessment by MRI ." J Comput Assist Tomogr. 1992 ; 16: 519-528.

59. Fajans SS. Diabetes mellitus: "Definition, classification, tests." In: DeGroot LJ (ed.). Endocrinology, 3rd edition. WB Saunders, Philadelphia 1995 ; 1412.

60. WHO Expert Committee on Diabetes mellitus. "Technical Report Series 646. Technical Report Series, World Health Organization." Geneva 1980 ; Second report 8-14.

61. Quabbe H-J. "Treatment of acromegaly by trans-sphenoidal operation, 90-Yttrium implantation and bromocriptine: Results in 230 patients." Clin Endocrinol. 1982 ; 16: 107-119.

62. Chang-DeMoranville BM, Jackson IMD. "Diagnosis and endocrine testing in acromegaly." In: Melmed S (ed) . Acromegaly. Endocrinology and Metabolism Clinics of North America. WB Saunders, Philadelphia 1992 ; 21: 649-668.

63. Masago A, Ueda Y, Kanai H, Nagai H, Umemura S. "Pituitary apoplexy after pituitary function test: A report of two cases and review of the literature." Surg Neurol. 1995 ; 43: 158-165.

64. Statistisches Landesamt Berlin . "Statistisches Jahrbuch 1992, Berlin." Statistisches Landesamt Berlin. Kulturbuch Verlag 1992 ; 54-55.

65. Plöckinger U, Holst JJ, Messerschmidt D, Hopfenmüller W, Quabbe H-J. "Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects." Eur J Endocrinol. 1999 ; 140: 538-544.

66. Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA ". Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: Outcome analysis and determinants of failure." J Neurosurg. 1993 ; 78: 205-215.

67. Davis DH, Laws ER, Ilstrup DM, Speed JK, Caruso M, Shaw EG, Abboud CF, Scheithauer BW, Root LM, Schleck C. "Results of surgical treatment for growth hormone-secreting pituitary adenomas." J Neurosurg. 1993 ; 79: 70-75.

68. Osman IA, James RA, Chatterjee S, Mathias D, Kendall-Taylor P. "Factors determining the long-term outcome of surgery for acromegaly." Q J Med. 1994 ; 87: 617-623.

69. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JAH. "Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure." Clin Endocrinol. 1996 ; 45: 407-413.

70. Swearingen B, Barker FG II, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, Moayeri N, Black PMCL, Zervas NT. "Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly." J Clin Endocrinol Metab. 1998 ; 83: 3419-3426.

71. Lembcke B, Creutzfeld W, Schleser S, Ebert R, Shaw C, Koop I. "Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary funtion and hormone release in normal men." Digestion. 1987 ; 36: 108-124

72. Plöckinger U, Dienemann D, Quabbe H-J. "Gastrointestinal side-effects of octreotide during long term treatment of acromegaly." J Clin Endocrinol Metab. 1990 ; 71: 1658-1662.

73. Plöckinger U, Liehr R-M, Quabbe H-J. Octreotide long-term treatment of acromegaly: "Effect of drug withdrawal on serum growth hormone/insulin-like growth factor -I concentrations and on serum gastrin/24-hour intragastric pH values." J Clin Endocrinol Metab. 1993 ; 77: 157-62.

74. Quabbe H-J, Schilling E, Helge H. "Pattern of growth hormone secretion during a 24-h fast in normal adults." J Clin Endocrinol Metab. 1966 ; 26: 1173-1177

75. Iranmanesh A, Grisso B, Veldhuis JD ". Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay." J Clin Endocrinol Metab. 1994 ; 78: 526-535.

76. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. "Enhanced sensitivity growth hormone (GH) chemiluminscence assay reveals lower postglucose nadir GH concentrations in men than women." J Clin Endocrinol Metab. 1994 ; 78: 1312-1319.

77. Edal AL, Skjodt K, Nepper-rasmussen HJ. "SIPAP - A new MR classification for pituitary adenomas. Suprasellar, infrasellar, parasellar, anterior and posterior." Acta Radiol. 1997 ; 38: 30-36.

78. Klijn JGM, Lamberts SWJ, de Jong FH, Dongen KJ van, Birkenhäger JC ". Interrelationship between tumour size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients." Acta Endocrinol. 1980 ; 95: 289-297.

79. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. "Transspenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initiale outcome and long-term results." J Clin Endocrinol Metab. 1998 ; 83: 3411-3418.

80. Laws ER Jr, Thapar K. "Pituitary surgery. " In: Molitch ME (ed .). Advances in the management of pituitary tumors. Endocrinology and Metabolism Clinics of North America. WB Saunders, Philadelphia 1999 ; 28

81. Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. End Rev. 1987 ; 8: 115-131.

82. Giovanelli M, Losa M, Mortini P ". Acromegaly: A surgical result and prognosis." In: Landolt AM, Vance M-L, Reilly P (eds.). Pituitary Adenomas: Biology, Diagnosis and Treatment . Churchill Livingstone, Edinburgh 1996 ; 333-351.

83. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Quart J Med, New Series. 1970 ; 39: 1-16.

84. Ross DA, Wilson CB. "Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas in a series of 214 patients. " J Neurosurg. 1988 ; 68: 854-867.

85. Freda PU, Wardlaw SL, Post KD. "Long-term endocrinological follow-up evaluation in 115 patients who underwent transphenoidal surgery for acromegaly." J Neurosurg. 1998 ; 89: 353-358.

86. Jenkins D, O'Brien I, Johnson A, Shakespear R, Sheppard MC, Stewart PM. "The Birmingham pituitary database: Auditing the outcome of the treatment of acromegaly. " Clin Endocrinol. 1995 ; 43: 517-522.

87. Guiot G, Bouche J, Oproiu A, Hertzog E, Ennuyer A, Anquez L, Trigo J-C. "Les indications de l'abord trans-spénoïdal des adénomes hypophysaires. " Presse medicale. 1967 ; 75: 1563-1567.

88. Hardy J. Transspenoidal hypopysectomy. J Neurosurg. 1971 ; 34: 582-594.

89. Valdemarsson S, Bramnert M, Cronquist S, Elner Å, Eneroth CM, Hedner P, Lindvall-Axelsson M, Nordström CH, Strömblad LG. "Early postoperative basal serum GH level and the GH response to TRH in relation to the long-term outcome of surgical treatment for acromegaly: A report in 39 cases." J Int Med. 1991 ; 230: 49-54.

90. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JRE, Shalet SM. "The outcome of surgery for acromegaly: The need for a specialist pituiatry surgeon for all types of growth hormone (GH) secreting adenoma." Clin Endocrinol. 1998 ; 49: 653-657.

91. Abe T, Lüdecke DK. "Recent primary transnasal surgical outcomes associated with intraoperative growth hormone measurement in acromegaly." Clin Endocrinol. 1999 ; 50: 27-35.

92. Giannella-Neto D, Wajchenberg BL, Mendonça BB, Almeida SF, Macchione M, Spencer EM. " Criteria for cure of acromegaly: Comparison between basal growth hormone and somatomedin C plasma concentrations in active and non-active acromegaly. " J Endocrinol Invest. 1988 ; 11: 57-60.

93. Rieu M, Girard F, Bricaire H, Binoux, M. "The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly." J Clin Endocerinol Metab. 1982 ; 55: 147-153.

94. Ho KKY, Weissberger AW. "Characterization of 24-hour growth hormone secretion in acromegaly: Implications for diagnosis and therapy. " Clin Endocrinol. 1994 ; 41: 75-83.

95. Buchfelder M, Brockmeier S, Fahlbusch R, Honegger J, Pichl J, Manzl M. "Recurrence following transsphenoidal surgery for acromegaly. " Horm Res. 1991 ; 35: 113-118.

96. Ahmed S, Elsheik M, Stratton IM, Page RCL, Adams CBT, Wass JAH. " Outcome od transspheoidal surgery for acromegaly and ist relationship to surgical experience." Clin Endocrinol. 1999 ; 50: 561-567.

97. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE. "Mortality and cancer incidence in acromegaly: A retrospective cohort study." J Clin Endocrinol Metab. 1998 ; 83: 2730-2734.

98. Greenman Y, Tordjman K, Kisch E, Razon N, Ouaknine G, Stern N. "Relative sparing of anterior pituitary function in patients with growth hormone -secreting macroadenomas: Comparison with nonfunctioning macroadenomas." J Clin Endocrinol Metab. 1995 ; 80: 1577-1583.

99. Yamada S, Aiba T, Takada K, Ozawa Y, Shimizu T, Sawano S, Shishiba Y, Sano T. "Retrospective analysis of long-term surgical results in acromegaly: Preoperative and postoperative factors predicting outcome." Clin Endocrinol. 1996 ; 45: 291-298.

100. Spinas GA, Zapf J, Landolt AM, Stuckmann G, Froesch ER. Pre-operative treatment of 5 acromegalics with a somatostatin analogue: Endocrine and clinical observations. Acta Endocrinol (Copenh.). 1987 ; 114: 249-256.

101. Ducasse MCR, Tauber JP, Tourre A, Bonafe A, Babin Th, Tauber MT, Harris AG, Bayard F. "Shrinkage of a growth hormone-producing pituitary tumor by continuous sucutaneous infusion of the somatostatin analog SMS 201-995." J Clin Endocrinol Metab. 1987 ; 65: 1042-1046.

102. Pelicci G, Pagliacci MC, Lanfrancone L, Pelicci PG, Grignani F, Nicoletti I. "Inhibitory effect of the somatostatin analog octreotide on rat pituitary tumor cell (GH3) proliferation in vitro. " J Endocrinol Invest. 1990 ; 13: 657-662.

103. Srikant CB. "Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituiatry cells." Biochem Biophys Res Com. 1995 ; 209: 400-406.

104. Anderson JV, Catnach S, Lowe DG, Fairclough PD, Besser GM, Wass JAH. "Prevalence of gastritis in patients with acromegaly: Untreated and during treatment with octreotide." Clin Endocrinol. 1992 ; 37: 227-232

105. Rhodes M, James RA, Bird M, Clayton B, Kendall-Taylor P, Lennard TWJ. "Gallbladder function in acromegalic patients taking long-term octreotide: Evidence of rebound hypermotility on cessation of treatment." Scand J Gastroenterol. 1992 ; 27: 115-118.

106. Plöckinger U, Perez-Canto A, Emde C, Liehr R-M, Hopfenmüller W, Quabbe H-J. "Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly." Eur J Endocrinol. 1998 ; 139: 387-394.

107. Colao A, Ferone D, Cappabianca P, Basso de Caro ML del, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, Divitiis E de, Lombardi G. "Effect of octreotide pretreatment on surgical outcome in acromegaly." J Clin Endocrinol Metab. 1997 ; 82: 3308-3314.

108. Biermasz NR, Dulken H van, Roelfsema F. "Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in matched controls." J Clin Endocrinol Metab. 1999 ; 84: 3551-3555.

109. Carvahlo D, Barbosa A, Freitas P, Machado-Carvahlo A, Baldaque-Faria A, Cruz J, Pina R, Cruz C, Medina J. "Preoperative octreotide treatment of acromegaly." J Endocrinol Invest. 1996 ; 19(Suppl 5): 12.

110. Reubi JC, Landolt AM. "The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status." J Clin Endocrinol Metab. 1989 ; 68: 844-850.

111. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Sarno A di, Longobardi S, Merola B, Salvatore M, Lombardi G. "Prediction of efficacy of octreotide therapy in patients with acromegaly." J Clin Endocrinol Metab. 1996 ; 81: 2356-2362.

112. Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe H-J. "Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone response to octreotide therapy and do not orrelate with tumor histology." Eur J Endocrinol. 1997 ; 136: 369-376.

113. Chanson P. "Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?." Eur J Endocrinol. 1997 ; 136: 359-361.

114. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF, Boyd AE, Sheeler L, Cook D, Malarkey WB, Jackson IMD, Vance ML, Thorner MO, Ho PJ, Jaffe CA, Frohman LA, Kleinberg DL. "Safety and efficacy of long term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study." J Clin Endocrinol Metab. 1995 ; 80: 2768-2775.

115. Vance ML, Harris AG. "Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. " Arch Int Med. 1991 ; 151: 1573-1578

116. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G, and the Italian Multicenter Octreotide Study Group. "Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. " Eur J Endocrinol. 1995 ; 133: 430-439.

117. Ho KY, Weissberger AJ, Marbach P, Lazarus L. "Therapeutic efficacy of the somatostatin analog SMS 201-995 (Octreotide) in acromegaly." Ann Int Med. 1990 ; 112: 173-181.

118. Brett M, Barker DJ. "The world distribution of gallstones." Int J Epidemiol. 1976 ; 5: 335-41

119. Hussaini SH, Pereira SP, Murphy GM, Kennedy C, Wass JAH, Besser GM, Dowling RH. "Composition of gall bladder stones associated with octreotide: Response to oral ursodeoxycholic acid." Gut. 1995 ; 36: 126-132.

120. James RA, Rhodes M, Rose P, Kendall-Taylor P. "Biliary colic on abrupt withdrawal of octreotide." Lancet. 1991 ; II 338: 1527.

121. Montini M, Gianola D, Pagani MD, Pedroncelli A, Caldara R, Gherardi F, Bonelli M, Lancranjan I, Pagani G. "Cholelithiasis and acromegaly: therapeutic strategies." Clin Endocrinol. 1994 ; 40: 401-406.

122. Ho KKY, Jenkins AB, Furler SM, Borkmann M, Chisholm DJ. "Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly." Clin Endocrinol. 1992 ; 36: 271-279.

123. Koop BL, Harris AG, Ezzat S. "Effect of octreotide on glucose tolerance in acromegaly." Eur J Endocrinol. 1994 ; 130: 581-586 .

124. Quabbe H-J, Plöckinger U. "Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly." J Clin Endocrinol Metab. 1989 ; 68: 873-881.

125. Oppizzi G, Liuzzi A, Chiodoni P, Dallabonzana D, Spelta B, Silvestrini F, Borghi G, Tonon C. "Dopaminergic treatment of acromegaly: Different effects on hormone secretion and tumor size." J Clin Endocrinol Metab. 1984 ; 58: 988-992.

126. Plöckinger U, Quabbe H-J. "Evaluation of a repeatable depot-bromocroptine preparation (Parlodel LAR®) for the treatment of acromegaly ." J Endocrinol Invest. 1991 ; 14: 943-948.

127. Jaspers C, Haase R, Pfingsten H, Benker G, Reinwein D. "Long-term treatment of acromegalic patients with repeatable parenteral depot-bromocriptine." Clin Invest. 1993 ; 71: 547-551.

128. Tsagarakis S, Tsiganou E, Tzavara I, Nikolou H, Thalassinos N. "Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas." Clin Endocrinol. 1995 ; 42: 593-599.

129. Abs R, Verhelst J, Maiter D,Van AK, Nobels F, Coolens JL, Mahler C, Beckers A. "Cabergoline in the treatment of acromegaly: A study in 64 patients." J Clin Endocrinol Metab. 1998 ; 83: 374-378

130. Jadresic A, Jimenez LE, Joplin GF. "Long-term effect of 90Y pituitary implantation in acromegaly." Acta Endocrinol (Copenh). 1987 ; 115: 301-306.

131. Thalassinos NC, Tsagarakis S, Ionnides G, Tzavara I, Papavasiliou C. "Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegaly: A long-term follow-up study." Eur J Endocrinol. 1998 ; 138: 160-163.

132. Littley MD, Shalet SM, Swindell R, Beardwell CG, Sutton ML. "Low-dose pituitary irradiation for acromegaly" . Clin Endocrinol. 1990 ; 32: 261-270.

133. Jackson IMD, Noreén G. "Role of gamma-knife therapy in the management of pituitary tumors." In: Molitch ME (ed.). Advances in the management of pituitary tumors. Endocrinology and Metabolism Clinics of North America. WB Saunders Philadelphia 1999 ; 28: 133-142.

134. Eastman RC, Gordon P, Roth J. "Conventional supervoltage irradiation is an effective treatment for acromegaly." J Clin Endocrinol Metab. 1979 ; 48: 931-940.

135. Kjellberg RN, Kliman B ". Treatment of acromegaly by proton hypophysectomy." In: Marley TP (ed.). Current controversies in neurosurgery. WB Saunders, Philadelphia 1976 ; 392-405.

136. Macleod AF, Clarke DG, Pambakian H, Lowy C, Sonksen PH, Collins CD. "Treatment of acromegaly by external irradiation ." Clin Endocrinol. 1989 ; 30: 303-314.

137. Morange-Ramos I, Régis J, Dufour H, Andrieu JM, Grisolo F, Jaquet P, Peragut JC. "Gamma-knife surgery for secreting pituitary adenomas." Acta Neurochir (Wien). 1998 ; 140: 437-443.

138. Ciaccarelli E, Corsello SM, Plowman PN, Jones AE, Touzel R, Rees LH, Besser GM, Wass JAH. "Long-term effects of radiotherapy for acromegaly on circulating prolactin." Acta Endocrinol (Copenh). 1989 ; 121: 827-832.

139. Voges J, Sturm V, Deuss U, Traud C, Treuer H, Schlegel W, Winkelmann W, Müller RP. "LINAC-radiosurgery (LINAC-RS) in pituitary adenomas: Preliminary results." Acta Neurochir (Wien). 1996 ; 65: 41-43.

140. Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, Wellis G. "Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated rdiotherapy." J Neurosurg. 1998 ; 88: 1002-1008.

141. Plowman PN. "Pituitary adenoma radiotherapy - when, who, and how." Clin Endocrinol. 1999 ; 51: 265-271.

142. Gramegna A. "Un cas d'acromégalie traité par la radiothérapie." Revue neurologique. 1909 ; 17: 15-17.

143. Béclère Dr. "Die Röntgenbehandlung der Hypophyengeschwülste, des Gigantismus und der Arkomegalie." Strahlentherapie. 1913 ; 3: 508-519.

144. Quick D. Radium and X-ray in tumors of the hypophsis. Arch Ophtalmol. 1920 ; 49: 256-267.

145. Forrest APM, Brown DAP. "Pituitary-radon implant for breast cancer ." Lancet . 1955 ; I : 1054-1055.

146. Molinatti GM, Camanni F, Massara F, Olivetti M, Pizzini A, Giuliani G. "Implantation of Yttrium 90 in the sella turcica in sixteen cases of acromegaly." J Clin Endocrinol Metab. 1962 ; 22: 599-611.

147. Forrest APM, Greenwood FC, Stewart HJ, Thomas JP, Wood RG, Thomas WRG, Bligh AS, Mitchell GM. "Pituitary implantation for pituitary tumours." Proc Royal Soc Med. 1965 ; 58: 475-480.

148. Hartog M, Doyle F, Fraser R, Joplin GF. "Partial pituitary ablation with implants of gold-198 and yttrium-90 for acromegaly" . Br Med J. 1965 ; 2: 396-398.

149. Cassar J, Doyle FH, Banks LM, Jadresic A, Mashiter K, Joplin GF. "Interstitial pituitary irradiation with 90Y for the treatment of acromegaly: A reappraisal." Acta Endocrinol. 1981 ; 96: 295-300.

150. Kaufman B, Pearson OH, Shealy CN, Chernak ES, Samaan N, Storaasli JP. "Transnasal-transsphenoidal Yttrium-90 pituitary implantation in the therapy of acromegaly." Radiology. 1966 ; 86: 915-920.

151. Kjellberg RN, Shintani A, Frantz AG, Kliman B. "Proton-beam therapy in acromegaly." New Engl J Med. 1968 ; 278: 689-695.

152. Dawson DM, Dingman JF. "Hazards of proton-beam pituitary irradiation." New Engl J Med. 1970 ; 282: 1434.

153. Braunstein GD, Loriaux DL. "Proton-beam therapy." New Engl J Med. 1971 ; 284: 332-333.

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.

DiML DTD Version 2.0
Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML - Version erstellt am:
Thu Sep 19 17:23:40 2002